ZUNBELRO Trademark
Trademark Overview
On Tuesday, November 28, 2023, a trademark application was filed for ZUNBELRO with the United States Patent and Trademark Office. The USPTO has given the ZUNBELRO trademark a serial number of 98288783. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Wednesday, August 7, 2024. This trademark is owned by Gilead Sciences Ireland UC. The ZUNBELRO trademark is filed in the Pharmaceutical Products category with the following description:
Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for treatment of gastrointestinal diseases and disorders
General Information
Serial Number | 98288783 |
Word Mark | ZUNBELRO |
Filing Date | Tuesday, November 28, 2023 |
Status | 653 - SUSPENSION LETTER - MAILED |
Status Date | Wednesday, August 7, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
Goods and Services | Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for treatment of gastrointestinal diseases and disorders |
Classification Information
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Monday, January 22, 2024 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
Party Name | Gilead Sciences Ireland UC |
Party Type | 10 - Original Applicant |
Legal Entity Type | 99 - Other |
Address | Carrigtohill, Co. Cork IE |
Trademark Events
Event Date | Event Description |
Friday, December 1, 2023 | NEW APPLICATION ENTERED |
Monday, January 22, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Wednesday, August 7, 2024 | LETTER OF SUSPENSION E-MAILED |
Wednesday, June 26, 2024 | ASSIGNED TO EXAMINER |
Wednesday, August 7, 2024 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
Wednesday, August 7, 2024 | SUSPENSION LETTER WRITTEN |
Monday, November 18, 2024 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |